What is HC Wainwright’s Estimate for PRQR FY2026 Earnings?

ProQR Therapeutics N.V. (NASDAQ:PRQR – Free Report) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for ProQR Therapeutics in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will earn ($0.44) per share for the year, down from their previous estimate of ($0.43). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS and FY2028 earnings at ($0.33) EPS.

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $4.30 million. ProQR Therapeutics had a negative return on equity of 72.78% and a negative net margin of 205.68%.

Other analysts also recently issued research reports about the stock. Bank of America started coverage on shares of ProQR Therapeutics in a research report on Thursday, August 20th. They issued a “buy” rating and a $8.00 price target for the company. Raymond James Financial restated a “strong-buy” rating on shares of ProQR Therapeutics in a report on Friday, November 13th. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, November 13th. Chardan Capital reaffirmed a “buy” rating and issued a $3.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Finally, Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.60.

Read Our Latest Report on PRQR

ProQR Therapeutics Stock Down 4.3%

Shares of NASDAQ:PRQR opened at $1.10 on Tuesday. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $2.48. The stock’s 50 day moving average is $1.52 and its 200-day moving average is $1.67. The firm has a market capitalization of $115.90 million, a price-to-earnings ratio of -2.50 and a beta of 0.29.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 11,186 shares during the last quarter. Walleye Capital LLC grew its position in ProQR Therapeutics by 2.7% during the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 15,744 shares during the period. Alpha Wealth Funds LLC purchased a new stake in ProQR Therapeutics during the third quarter worth about $41,000. Axiom Investment Management LLC purchased a new stake in ProQR Therapeutics during the first quarter worth about $53,000. Finally, RFG Advisory LLC increased its holdings in ProQR Therapeutics by 236.8% during the second quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 45,000 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

(Get Free Report)

ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.

Read More

Earnings History and Estimates for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.